



Make it  
better together

**TRUE EXTRACTS OF THE MEETING OF THE 169<sup>TH</sup> MEETING OF THE BOARD OF DIRECTORS OF SAI LIFE SCIENCES LIMITED HELD AT SHORTER NOTICE ON TUESDAY, THE 4<sup>TH</sup> JULY, 2024 AT 4.30 PM AT THE CORPORATE OFFICE OF THE COMPANY AT #L4-01 & 02, SLN TERMINUS, SURVEY #133, GACHIBOWLI MIYAPUR ROAD, GACHIBOWLI, HYDERABAD – 500032, TELANGANA THROUGH VIDEO CONFERENCE.**

## **CONSIDERATION AND APPROVAL OF THE INITIAL PUBLIC OFFERING OF EQUITY SHARES OF THE COMPANY**

**RESOLVED THAT**, subject to approval of the shareholders of the Company and pursuant to the provisions of Sections 23, 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013 to the extent notified and as amended, and the rules and regulations made thereunder, as amended including the Companies (Prospectus and Allotment of Securities) Rules, 2014, as amended, the Companies (Share Capital and Debentures) Rules, 2014, as amended, , and the rules and regulations made thereunder, if any (including any statutory modifications or re-enactment thereof, for the time being in force) (the “**Companies Act**”), and in accordance with and subject to the provisions of the Securities Contracts (Regulation) Act, 1956, and the rules made thereunder, including the Securities Contracts (Regulation) Rules, 1957, each as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “**SEBI ICDR Regulations**”), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“**SEBI Listing Regulations**”) and any other applicable rules, regulations, guidelines, clarifications, circulars and notifications issued by the Reserve Bank of India (“**RBI**”), the Foreign Exchange Management Act, 1999, as amended (the “**FEMA**”) including the Foreign Exchange Management (Non debt Instruments) Rules, 2019, the Foreign Exchange Management (Transfer or Issue of Security by a Person Resident Outside India) Regulations, 2017, as amended, the Securities and Exchange Board of India (“**SEBI**”) and any other applicable laws, rules and regulations, policies, guidelines including any foreign investment law, clarifications, directions, circulars, orders and notifications issued by the Government of India (“**Gol**”), including the Department for Promotion of Industry and Internal Trade, the Registrar of Companies, Telangana at Hyderabad (“**RoC**”), SEBI, the Department of Economic Affairs, Ministry of Finance, Government of India (“**DEA**”), RBI or Stock Exchanges and any other applicable laws, policies, rules and regulations, in India or outside India (including any amendment thereto or re-enactment thereof for the time being in force) (collectively, the “**Applicable Laws**”), and in accordance with the provisions of the Memorandum of Association and the Articles of Association of the Company and the uniform listing agreements to be entered into between the Company and the respective stock exchanges where the Equity Shares are proposed to be listed (the “**Stock Exchanges**”), and subject to any approvals as may be required from the Gol, the RoC, the SEBI, the RBI and all other appropriate statutory authorities and departments (collectively, the “**Regulatory Authorities**”) and subject to such governmental and regulatory conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approvals, consents, permissions and sanctions and which may be agreed to by the Board of Directors (hereinafter referred to as the “**Board**” which term shall include a duly authorized committee thereof for the time being exercising the powers conferred by the Board including the powers conferred by this resolution), the consent and approval of the Board be and is hereby accorded to create, issue, offer and allot equity shares of face value of ₹ 1/- each (the “**Equity Shares**”) which may include a [fresh issue of Equity Shares (the “**Fresh Issue**”) and an offer for sale of Equity Shares (“**Offer for Sale**”) by certain shareholders of the Company (the “**Selling Shareholders**”) (the “**Offer for Sale**” and together with the Fresh Issue, the “**Offer**”)] in the Offer (the “**Offer**”), for cash either at par or premium such that the amount being raised pursuant to the Fresh Issue aggregates up to Rs.8000 million (including share premium) (with an option to the Company to retain an over-subscription to the extent of 1% of the net Offer, for the purpose of rounding off to the nearest integer to make allotment while finalizing the basis of allotment in consultation with the designated stock exchange), together with an offer for sale, up to an aggregate 6,15,63,120 Equity Shares comprising of an offer for sale by certain existing shareholders of our Company (collectively, the “**Selling Shareholders**” and such offer for sale, the “**Offer for Sale**” the Offer for Sale together with the Fresh Issue, the “**Offer**”), at a price to be determined, by the Company

### **Sai Life Sciences Limited**

CIN: U24110TG1999PLC030970

Registered Office:

Plot No.DS-7, IKP Knowledge Park,  
Turkapally (V), Shameerpet Mandal,  
Medchal-Malkajgiri Dist-500078,  
Telangana, India.

T: +91 40 6815 6000,

F: +91 40 6815 6199

E: [info@sailife.com](mailto:info@sailife.com)  
[www.sailife.com](http://www.sailife.com)

Corporate Office:

# L4-01&02, SLN Terminus, Survey #133,  
Gachibowli Miyapur Road, Gachibowli,  
Hyderabad-500032, Telangana, India.



Make it  
better together

in consultation with the BRLMs, through the book building process in terms of the SEBI ICDR Regulations or otherwise in accordance with Applicable Laws, at such premium or discount per Equity Share as permitted under Applicable Laws and as may be fixed and determined by the Company in consultation with the BRLMs in accordance with the SEBI ICDR Regulations, out of the authorized share capital of the Company to any category of person or persons as permitted under Applicable Laws, who may or may not be the shareholder(s) of the Company as the Board may, decide, including anchor investors and qualified institutional buyers as defined under Regulations 2(1)(c) and 2(1)(ss), respectively of the SEBI ICDR Regulations, foreign / resident investors (whether institutions, incorporated bodies, mutual funds and/or individuals or otherwise) one or more of the members of the Company, eligible employees (through a reservation or otherwise), hindu undivided families, foreign portfolio investors (other than individuals, corporate bodies and family offices), venture capital funds, alternative investment funds, non-resident Indians, registered foreign portfolio investors as defined under the Securities and Exchange Board of India (Foreign Portfolio Investors) Regulations, 2019, as amended, registered alternative investment funds, venture capital funds, foreign venture capital investors, public financial institutions as specified in Section 2(72) of the Companies Act, scheduled commercial banks, state industrial development corporations, insurance companies registered with the Insurance Regulatory and Development Authority of India, provident funds with minimum corpus of twenty five crore rupees, pension funds with minimum corpus of twenty five crore rupees and registered with the Pension Fund Regulatory and Development Authority, National Investment Fund, insurance funds set up by army, navy, or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India, trusts/societies registered under the Societies Registration Act, 1860, as amended, development financial institutions, systemically important non-banking financial companies, Indian mutual funds, multilateral and bilateral development financial institution, Indian public, bodies corporate, companies (private or public) or other entities (whether incorporated or not), authorities, and to such other persons including high net worth individuals, retail individual bidders or other entities, in one or more combinations thereof and/or any other category of investors as may be permitted to invest under Applicable Laws by way of the Offer in consultation with the BRLMs and/or underwriters and/or the stabilizing agent and/or other advisors or such persons appointed for the Offer and on such terms and conditions as may be finalised by the Board in consultation with the BRLMs through an offer document, prospectus and/or an offering memorandum, as required, and that the Board in consultation with the BRLMs may finalise all matters incidental thereto as it may in its absolute discretion think fit."

**"RESOLVED FURTHER THAT** the Board and such other persons as may be authorised by the Board be and is hereby authorized on behalf of the Company to make available for allocation a portion of the Offer to any category(ies) of persons permitted under Applicable Law, including without limitation, eligible employees (the **"Reservation"**) or to provide a discount to the Offer price to retail individual bidders or eligible employees (the **"Discount"**), at the discretion of the Board; and to take any and all actions in connection with any Reservation or Discount as the Board may think fit or proper in its absolute discretion, including, without limitation, to negotiate, finalize and execute any document or agreement, and any amendments, supplements, notices or corrigenda thereto; seek any consent or approval required or necessary; give directions or instructions and do all such acts, deeds, matters and things as the Board may, from time to time, in its absolute discretion, think necessary, appropriate, or desirable; and settle any question, difficulty, or doubt that may arise with regard to or in relation to the foregoing."

**"RESOLVED FURTHER THAT** subject to the approval of shareholders in a general meeting, in accordance with the provisions of Sections 23, 42, 62(1)(c), and any other applicable provisions, if any, of the Companies Act, 2013, and subject to such further corporate and other approvals as may be required, in-principle approval of the Board is hereby accorded to allot up to up to an aggregate 6,15,63,120 Equity Shares for an amount aggregating up to Rs. Rs.8000 million to certain investors on or prior to filing of the red herring prospectus with SEBI (**"Pre-IPO Placement"**), at such other price as the Board may, determine, in consultation with the BRLMs, the Selling Shareholders, underwriters, placement

#### Sai Life Sciences Limited

CIN: U24110TG1999PLC030970

Registered Office:

Plot No.DS-7, IKP Knowledge Park,  
Turkapally (V), Shameerpet Mandal,  
Medchal-Malkajgiri Dist-500078,  
Telangana, India.

T: +91 40 6815 6000,

F: +91 40 6815 6199

E: [info@sailife.com](mailto:info@sailife.com)  
[www.sailife.com](http://www.sailife.com)

Corporate Office:

# L4-01&02, SLN Terminus, Survey #133,  
Gachibowli Miyapur Road, Gachibowli,  
Hyderabad-500032, Telangana, India.





Make it  
better together

agents and / or other advisors, in light of the then prevailing market conditions and in accordance with the Companies Act, the SEBI ICDR Regulations and other applicable laws, regulations, policies or guidelines and in the event of the consummation of the Pre-IPO Placement, the size of the Offer would be reduced to the extent of Equity Shares issued and subscribed under the Pre-IPO Placement, and to take any and all actions in connection with the Pre-IPO Placement as the Board or the IPO Committee may think fit or proper in its absolute discretion, including, without limitation, to negotiate, finalize and execute any document or agreement, and any amendments, supplements, notices or corrigenda thereto, including without limitation any private placement offer letters, placement agreement, escrow agreement, term sheet and such other documents or any amendments or supplements thereto and to open any bank account for the purpose if required, and to open any shares or securities account or escrow or custodian accounts as may be required in connection, to seek any consent or approval required or necessary, to give directions or instructions and do all such acts, deeds, matters and things as the Board or the IPO Committee may, from time to time, in its absolute discretion, think necessary, appropriate, or desirable, and to settle any question, difficulty, or doubt that may arise with regard to or in relation to the foregoing resolution. It is clarified that, in the event of a Pre-IPO Placement, the size of the Offer would be reduced, only from the Fresh Issue portion of the Offer, to the extent of Equity Shares issued under the Pre-IPO Placement, subject to the Offer satisfying the minimum issue size requirements under the SCRR.”

**RESOLVED FURTHER THAT**, the Board may invite the existing shareholders of the Company to participate in the Offer by making an Offer for Sale in relation to such number of Equity Shares held by them, and which are eligible for the Offer for Sale in accordance with the SEBI ICDR Regulations, as the Board may determine in consultation with the BRLMs, subject to the receipt of consent of SEBI, Gol, RBI, the RoC and/or such other approvals, permissions and sanctions of all other concerned statutory authorities and departments, if and to the extent necessary, and subject to such conditions and modifications as may be prescribed in granting such approvals, permissions and sanctions, at a price to be determined by the book building process in terms of the SEBI ICDR Regulations, for cash at such premium per share as may be fixed and determined by the Company in consultation with the BRLMs, to such category of persons as may be permitted or in accordance with the SEBI ICDR Regulations or other Applicable Laws, if any, as may be prevailing at that time and in such manner as may be determined by the Board in consultation with the BRLMs and/or underwriters and/or the stabilizing agent and/or other advisors or such persons appointed for the Offer.

**“RESOLVED FURTHER THAT** the Equity Shares so allotted or transferred pursuant to the Offer shall be listed on one or more recognized stock exchanges in India.”

**“RESOLVED FURTHER THAT** the Equity Shares so allotted under the Offer (including any reservation or green shoe option) shall be subject to the memorandum of association of the Company and the articles of association of the Company and shall rank *pari passu* in all respects with the existing Equity Shares of the Company including rights in respect of dividend.”

**“RESOLVED FURTHER THAT** for the purpose of giving effect to the above resolutions and any issue, transfer and allotment of Equity Shares pursuant to the Offer, the Board, or any committee thereof, in consultation with the BRLMs, may determine the terms of the Offer including the class of investors to whom the Equity Shares are to be allotted or transferred, the number of Equity Shares to be allotted or transferred, Offer price, premium amount, discount (as allowed under Applicable Laws), listing on one or more stock exchanges in India as the Board in its absolute discretion deems fit and do all such acts, deeds, matters and things and to negotiate, finalize and execute such deeds, documents agreements and any amendment thereto, as it may, in its absolute discretion, deem necessary, proper or desirable including arrangements with BRLMs, underwriters, escrow agents, legal advisors, etc., to approve incurring of expenditure and payment of fees, commissions, brokerage, remuneration and reimbursement of expenses in connection with the Offer and to settle or give instructions or directions for settling any questions, difficulties or doubts that may arise, in regard to the Offer, transfer and

#### Sai Life Sciences Limited

CIN: U24110TG1999PLC030970

Registered Office:

Plot No.DS-7, IKP Knowledge Park,  
Turkapally (V), Shameerpet Mandal,  
Medchal-Malkajgiri Dist-500078,  
Telangana, India.

T: +91 40 6815 6000,

F: +91 40 6815 6199

E: [info@sailife.com](mailto:info@sailife.com)  
[www.sailife.com](http://www.sailife.com)

Corporate Office:

# L4-01&02, SLN Terminus, Survey #133,  
Gachibowli Miyapur Road, Gachibowli,  
Hyderabad-500032, Telangana, India.



**Make it  
better together**

allotment of the Equity Shares, and utilization of the Offer proceeds, if applicable and such other activities as may be necessary in relation to the Offer and to accept and to give effect to such modifications, changes, variations, alterations, deletions and/or additions as regards the terms and conditions as it may, in its absolute discretion, deem fit and proper in the best interest of the Company and the Offer, without requiring any further approval of the shareholders, except as required under law, and that all or any of the powers conferred on the Board pursuant to these resolutions may be exercised by the Board or such committee thereof as the Board may constitute in its behalf."

**"RESOLVED FURTHER THAT** subject to compliance with Applicable Laws such Equity Shares as are not subscribed may be disposed of by the Board in consultation with the BRLMs to such persons and in such manner and on such terms as the Board in its absolute discretion thinks most beneficial to the Company including offering or placing them with banks/ financial institutions/ investment institutions/ mutual funds/ foreign portfolio investors / bodies corporate/ such other persons or otherwise."

**"RESOLVED FURTHER THAT** in connection with any of the foregoing resolutions, the members of the Board and such other persons as may be authorized by the Board, on behalf of the Company, be and are hereby severally authorized to execute and deliver any and all other documents, papers or instruments, issue and provide certificates and to do or cause to be done any and all acts or things as may be necessary, appropriate or advisable in order to carry out the purposes and intent of the foregoing resolutions for the Offer; and any such documents so executed and delivered or acts and things done or caused to be done shall be conclusive evidence of the authority of the Company in so doing and any document so executed and delivered or acts and things done or caused to be done prior to the date hereof are hereby ratified, confirmed and approved as the acts and deeds of the Company, as the case may be."

**"RESOLVED FURTHER THAT** a copy of the above resolution, certified to be true by any Director or Company Secretary, be forwarded to concerned authorities for necessary actions."

**//CERTIFIED TRUE COPY//**

**For Sai Life Sciences Limited**



**Runa Karan**

**Company Secretary**

**Mem No:A13721**

**Sai Life Sciences Limited**

CIN: U24110TG1999PLC030970

Registered Office:

Plot No.DS-7, IKP Knowledge Park,  
Turkapally (V), Shameerpet Mandal,  
Medchal-Malkajgiri Dist-500078,  
Telangana, India.

T: +91 40 6815 6000,

F: +91 40 6815 6199

E: [info@sailife.com](mailto:info@sailife.com)  
[www.sailife.com](http://www.sailife.com)

Corporate Office:

# L4-01&02, SLN Terminus, Survey #133,  
Gachibowli Miyapur Road, Gachibowli,  
Hyderabad-500032, Telangana, India.

**EXTRACTS FROM THE MINUTES OF THE 173<sup>rd</sup> MEETING OF THE BOARD OF DIRECTORS OF SAI LIFE SCIENCES LIMITED HELD AT SHORTER NOTICE ON TUESDAY, THE 12<sup>th</sup> DAY OF NOVEMBER, 2024 AT 9.00 AM AT THE CORPORATE OFFICE OF THE COMPANY AT #L4-01 & 02, SLN TERMINUS, SURVEY #133, GACHIBOWLI MIYAPUR ROAD, GACHIBOWLI, HYDERABAD – 500032, TELANGANA THROUGH VIDEO CONFERENCE.**

---

The Chairman informed the members that the Company had received approval from the Board and Shareholders to raise as Initial Primary capital of Rs. 800 Crores and the same has been filed with SEBI as part of the DRHP. The objective of the primary raise is to reduce the debt while retaining an amount of Rs 200 Crores for general corporate purposes. The Company now plans to increase the Initial Primary issue to Rs. 950 Crores and use the proceeds to repay debt upto Rs. 720 Crores and increase the amounts kept for general corporate purposes to Rs. 230 crores. The ICDR regulations permit the Company to increase this primary raise up to 20% from the amounts specified in the DRHP and hence the company will be in compliance with the ICDR regulations.

He further stated that the increase in the Initial Primary Capital will be subject to the approval of the shareholders. The members after discussion approved the increase and passed the following resolution:

**“RESOLVED THAT** in furtherance of the resolution passed by the board of directors of the Company (**“Board”**) on July 4, 2024 approving the initial public offering of equity shares of face value of ₹1 each of the Company (**“Equity Shares”**) comprising a fresh issue of up to ₹8,000 million (**“Fresh Issue”**) and an offer for sale of Equity Shares by certain shareholders of the Company (**“Offer for Sale”** and together with the Fresh Issue, the **“Offer”**) and the special resolution passed by the shareholders of the Company on July 4, 2024 approving the Fresh Issue, and pursuant to the provisions of the Companies Act, 2013 and the rules made thereunder, as amended, the Securities Contracts (Regulation) Act, 1956, and the rules framed thereunder, each as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and any other applicable laws, rules and regulations, in India or outside India (including any amendment thereto or re-enactment thereof, for the time being in force), the provisions of the Memorandum of Association and Articles of Association of the Company and the uniform listing agreements to be entered into between the Company and the respective stock exchanges where the Equity Shares of the Company are proposed to be listed and subject to approval of the shareholders of the Company, the consent and approval of the Board be and is hereby accorded to modify the offer size and accordingly, create, issue, offer and allot such number of equity shares, for cash either at par or premium such that the amount being raised pursuant to the Fresh Issue aggregates up to ₹ 9600 million at a price to be determined in accordance with the book building process in terms of the applicable laws, to such category of persons/ investors who may or may not be shareholders of the Company, including reservations in favour of eligible investors, for cash at a price as may be fixed and determined by the Company in consultation with the book running lead managers.

**RESOLVED FURTHER THAT** in connection with any of the foregoing resolutions, the Board and such other persons as may be authorised by the Board, on behalf of the Company, be and are hereby severally authorised to execute and deliver any and all other documents, papers or instruments, issue and provide certificates and to do or cause to be done any and all acts or things as may be necessary, appropriate or advisable in order to carry out the purposes and intent of the foregoing resolutions for **Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally (V),  
Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: [info@sailife.com](mailto:info@sailife.com)  
W: [www.sailife.com](http://www.sailife.com)



# Sai

Make it  
better  
together

the Offer, and any such documents so executed and delivered or acts and things done or caused to be done shall be conclusive evidence of the authority of the Company in so doing and any document so executed and delivered or acts and things done or caused to be done prior to the date hereof are hereby ratified, confirmed and approved as the acts and deeds of the Company, as the case may be.

**RESOLVED FURTHER THAT** any director, Chief Financial Officer and/or Company Secretary of the Company be and hereby authorised to certify the true copy of the aforesaid resolutions.

**//CERTIFIED TRUE COPY//**  
**For Sai Life Sciences Limited**

**Runa Karan**  
**Company Secretary**  
**Mem No: A13721**



**Sai Life Sciences Limited** (CIN: U24110TG1999PLC030970)

**Corporate office**

# L4-01 & 02, SLN Terminus, Survey  
#133, Gachibowli Miyapur Road,  
Gachibowli, Hyderabad – 500032,  
Telangana, India.

**Registered office**

Plot No. DS-7, IKP Knowledge Park, Turkapally (V),  
Shameerpet Mandal, Medchal-Malkajgiri  
(Dist), Hyderabad -500078, Telangana, India.

**Contact us**

T: +91 40 6815 6000,  
F: +91 40 6815 6199  
E: [info@sailife.com](mailto:info@sailife.com)  
W: [www.sailife.com](http://www.sailife.com)